EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A TrkB and TrkC partial agonist restores deficits in synaptic function and promotes activity‐dependent synaptic and microglial transcriptomic changes in a late‐stage Alzheimer's mouse model

Amira Latif-Hernandez, Tao Yang, Robert R Butler, Patricia Moran Losada, Paras S Minhas, Halle White, Kevin C Tran, Harry Liu, Danielle A Simmons, Vanessa Langness, Katrin I Andreasson, Tony Wyss-Coray und 1 weitere

Alzheimer's & Dementia · 2024

DOI: 10.1002/alz.13857 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Amira Latif-Hernandez und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology & Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Microglia, Receptor, trkB, Synapses. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Scully Family Initiative, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Tropomyosin related kinase B (TrkB) and C (TrkC) receptor signaling promotes synaptic plasticity and interacts with pathways affected by amyloid beta (Aβ) toxicity. Upregulating TrkB/C signaling could reduce Alzheimer's disease (AD)‐related degenerative signaling, memory loss, and synaptic dysfunction. METHODS PTX‐BD10‐2 (BD10‐2), a small molecule TrkB/C receptor partial agonist, was orally administered to aged London/Swedish‐APP mutant mice (APP L/S ) and wild‐type controls. Effects on memory and hippocampal long‐term potentiation (LTP) were assessed using electrophysiology, behavioral studies, immunoblotting, immunofluorescence staining, and RNA sequencing. RESULTS In APP L/S mice, BD10‐2 treatment improved memory and LTP deficits. This was accompanied by normalized phosphorylation of protein kinase B (Akt), calcium‐calmodulin–dependent kinase II (CaMKII), and AMPA‐type glutamate receptors containing the subunit GluA1; enhanced activity‐dependent recruitment of synaptic proteins; and increased excitatory synapse number. BD10‐2 also had potentially favorable effects on LTP‐dependent complement pathway and synaptic gene transcription. DISCUSSION BD10‐2 prevented APP L/S /Aβ‐associated memory and LTP deficits, reduced abnormalities in synapse‐related signaling and activity‐dependent transcription of synaptic genes, and bolstered transcriptional changes associated with microglial immune response. Highlights Small molecule modulation of tropomyosin related kinase B (TrkB) and C (TrkC) restores long‐term potentiation (LTP) and behavior in an Alzheimer's disease (AD) model. Modulation of TrkB and TrkC regulates synaptic activity‐dependent transcription. TrkB and TrkC receptors are candidate targets for translational therapeutics. Electrophysiology combined with transcriptomics elucidates synaptic restoration. LTP identifies neuron and microglia AD‐relevant human‐mouse co‐expression modules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseMicrogliaReceptor, trkBSynapsesAnimalsMaleMiceDisease Models, AnimalHippocampusLong-Term PotentiationMice, TransgenicNeuronal PlasticityReceptor, trkCTranscriptome

Stichwörter der Autor:innen

activity‐dependent gene expressionamyloid beta‐induced synaptic dysfunctiontropomyosin related kinase B and C receptor signaling

Substanzen

Ntrk2 protein, mouseReceptor, trkBReceptor, trkC

Autor:innen und Institutionen

  • Department of Neurology & Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
  • Wu Tsai Neurosciences Institute, Stanford University, Stanford, California, USA.
  • Chan Zuckerberg Biohub, San Francisco, California, USA.
  • The Phil and Penny Knight Initiative for Brain Resilience, Stanford University, Stanford, California, USA.

Förderung

  • NIA NIH HHS
  • Scully Family Initiative
  • NIH HHS
  • NINDS NIH HHS
  • Taube Family Foundation
  • Horngren Family
  • NIGMS NIH HHS
  • Michael J Fox foundations

Zitieren

APA

Latif-Hernandez, A., Yang, T., Butler, R. R., Losada, P. M., Minhas, P. S., White, H., Tran, K. C., Liu, H., Simmons, D. A., Langness, V., Andreasson, K. I., Wyss-Coray, T., & Longo, F. M. (2024). A TrkB and TrkC partial agonist restores deficits in synaptic function and promotes activity‐dependent synaptic and microglial transcriptomic changes in a late‐stage Alzheimer's mouse model. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13857

Vancouver

Latif-Hernandez A, Yang T, Butler RR, Losada PM, Minhas PS, White H, et al. A TrkB and TrkC partial agonist restores deficits in synaptic function and promotes activity‐dependent synaptic and microglial transcriptomic changes in a late‐stage Alzheimer's mouse model. Alzheimer's & Dementia. 2024. doi:10.1002/alz.13857

BibTeX
@article{LatifHernandez2024,
  author = {Latif-Hernandez, Amira and Yang, Tao and Butler, Robert R and Losada, Patricia Moran and Minhas, Paras S and White, Halle and Tran, Kevin C and Liu, Harry and Simmons, Danielle A and Langness, Vanessa and Andreasson, Katrin I and Wyss-Coray, Tony and Longo, Frank M},
  title = {A TrkB and TrkC partial agonist restores deficits in synaptic function and promotes activity‐dependent synaptic and microglial transcriptomic changes in a late‐stage Alzheimer's mouse model},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  doi = {10.1002/alz.13857}
}
Kostenlos starten →